Paragon Care (PGC)
    1. sevilla2014 sevilla2014 está desconectado
  • Buenas:
    He estado mirando una compañía australiana de ciencias de la salud. Me parece muy interesante y quiero entrar esta noche. Están a punto de publicar el cuarto trimestre. En principio la veo bien para el medio y largo plazo. Llevan años creciendo por la diversificación, expansión y adquisiciones de otras empresas relacionadas con el sector.
    El sector salud sufre buen crecimiento en Austalia y Nueva Zelanda. Ellos llevan desde ropa y utilidades para hospitales, hasta material quirúrgico, ecógrafos, oftalmología, etc. Gran variedad de productos.
    Pongo resumen
    Ultimas adquisiciones:
    Paragon Care has acquired eleven businesses over the past seven years, each one a leading provider of innovative healthcare and medical equipment. The businesses are:

    Designs For Vision
    GM Medical
    Iona Medical
    LR Instruments
    Richards Medical
    Western Biomedical


    Los balances de los últimos años son buenos. El último informe financiero :Espectacular el crecimiento experimentado,Net Profit after tax of $7.5M up 257% over the prior year

    Highlights for the year ended 30 June 2016 included:
    - Revenue up 190% to 93.4M.
    - EBITDA of $12.1M, up 224% over the prior period and slightly ahead
    of market guidance.
    - Net Profit after tax of $7.5M up 257% over the prior year.
    - Earnings per share of 5.6 cents, up 75%.
    - The Company’s balance sheet remains sound with cash at year-end
    of $19.1M
    - Paragon’s share price increased 18% over the course of the
    financial year as investors continued to embrace our story.
    - Fully franked dividends for the year of 2.2 cents, up 57% from the
    1.4 cents in the prior year.
    - Paragon was admitted into the ASX All Ordinaries index, which
    gives the company a wider access to capital as it grows.

    Los ratios financieros me parecen buenos, per aún bajo para el crecimiento esperado, deuda controlada, roe roa bien, etc.

    Per 14, evolución en ventas, ebitda desde 2015

    2015 2016 2017 2018 2019
    Sales 32,2 93,4 124 134 143
    Operating income (EBITDA) 3,70 12,1 17,8 19,4 20,7
    ROA (Net Profit / Asset) 6,83% 8,07%
    ROE (Net Profit / Equities) 12,8% 13,2%

    En su web viene todo más detallado, todos los balances de los últimos años, buen crecimiento por acción.

    Ultimas noticias:

    Grafico cotización

    1. sevilla2014 sevilla2014 está desconectado
  • He aprovechado las rebajas para comprar. Ha publicado resultados, son buenos, pero ha bajado un 11%, pienso que es porque se esperaban mejores, los anteriores fueron espectaculares, Pero a estos precios me parece interesante, por lo menos para mí.

    Pongo resultados : Son buenos

    Revenue of $55.0m, up 43% over 1H16 ‒ Underpinned by strong organic EBITDA growth of 14% on a like for like basis over
    the prior corresponding period which includes a full half year contribution from
    Western Biomedical, Designs for Vision and Meditron ‒ Second half expected to be stronger than first half given historical trends and the
    seasonal nature of hospital procurement
     EBITDA of $6.7m, up 46% over 1H16; EBITDA margin in excess of 12% maintained as
    integration of recently acquired businesses continues
     Fully franked dividend of 1.1c, representing a 48% payout of NPAT
     Continuing to provide significant earnings upside through successful acquisitions ‒ Now in a position to fund acquisition opportunities internally through operating
    cash flows, subject to size, which continue to deliver strong growth in EPS and DPS ‒ Recent acquisitions in 1H17, Electro Medical and MIDAS, were funded internally
    through strong operational cash flows and scrip respectively
     FY17 expected revenue: $115m-120m, driven by strong double digit organic growth
    and successful integration of recent acquisitions
     FY17 expected EBITDA: $15.7m-16.7m, leveraging platform economics as marginal
    revenue drives stronger EBITDA to revenue margins

    1. sevilla2014 sevilla2014 está desconectado
  • Ya sabía yo que es buen precio de entrada, 4% arriba
    1. sevilla2014 sevilla2014 está desconectado
  • Sigue a punto de cerrar el gap del otro dia, ya está en 78c
    1. colombo1122 colombo1122 está desconectado
  • Esta se va para abajo, sin fallo, ha roto la resis sin volumen, y ahora nube oscura.
    Esta a 0,795
    1. sevilla2014 sevilla2014 está desconectado
  • si claro y mañana, lloverá por Madrid?
    1. colombo1122 colombo1122 está desconectado
  • D momento hoy bajando, visita los 76 fijo
    1. sevilla2014 sevilla2014 está desconectado
  • What Investors Should Know About Paragon Care Limited’s (ASX:PGC) Financial Strength?
    Michael Canly May 29, 2017
    Paragon Care Limited (ASX:PGC) is a small-cap-stock with a market capitalization of USD $87 Million. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. There are always disruptions which destabilize and many a times end an existing industry, and most small-cap companies are the first casualties when such a wave hits.

    Apart from geopolitical events such as political unrest and natural calamities, a company which is suddenly facing a hostile market environment must be able to fulfil short-term commitments with its reserves so that it can see another day. Thus, it becomes utmost important for an investor to test a company’s resilience for such contingencies. In simple terms, I believe these three small calculations tell most of the story you need to know.
    See our latest analysis for PGC
    Does PGC generate enough cash through operations to meet all its needs?

    More than the revenue shown on paper, what matters is how much cash is generated through operations and whether it is enough to continue operations, meet debt-obligations and fund growth. Over the past year, Paragon Care’s operating cash flows stood at 21.6% of its overall debt. That means Paragon Care’s core operations are generating enough cash to comfortably service its debt.

    Paragon Care (ASX:PGC) Historical Debt May 29th 17

    Paragon Care (ASX:PGC) Historical Debt May 29th 17

    Does PGC’s cash and short-term assets cover its short-term commitments?

    While failure to manage cash has been one of the major reasons behind the demise of a lot of small businesses, the mismanagement comes into the limelight during tough situations such as economic recession, war, natural disaster, sudden increase in the price of raw materials, and a supply chain risk, which can put a company in a difficult situation. However, banks, creditors, wages, and commitment to suppliers do not go away even during an extreme event. So, a company must maintain enough liquidity to meet its short-term obligations to survive. Paragon Care is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

    Paragon Care (ASX:PGC) Net Worth May 29th 17

    Paragon Care (ASX:PGC) Net Worth May 29th 17

    Can PGC service its debt comfortably?

    While ideally I reckon the debt-to equity ratio of a financially healthy company to be less than 40%, several factors such as industry life-cycle and economic conditions can result in a company raising a significant amount of debt. For Paragon Care, the debt to equity ratio is 47.8% and this indicates that Paragon Care’s debt is at an acceptable level. No matter how high is the debt, if a company can easily cover the interest payments, it’s considered to be making a good use of that excessive leverage. To keep an eye on how it’s doing on that front, an investor can check how easily the company can service its debt. If it earns at least 5x or more of its interest payments, that’s an indication of financial strength. In PGC’s case the interest on debt is well covered by earnings (7.3x coverage).


    Whilst Paragon Care’s debt to equity ratio is high for my liking, it’s interest costs are well covered by it’s net income and the company’s operating cash flows are strong enough to fuel it’s future growth activities or pay dividends. Overall it’s in a strong financial position.

    Now when you know whether you should keep the debt in mind as a risk factor when putting together your investment thesis, I recommend you check out our latest free analysis report on Paragon Care to see what are PGC’s growth prospects and whether it could be considered an undervalued opportunity

    1. sevilla2014 sevilla2014 está desconectado
  • Poco a poco se acerca a los máximos del año
    1. sevilla2014 sevilla2014 está desconectado
  • Valuation 2017e 2018e
    P/E ratio (Price / EPS) 13,6x 11,6x
    Capitalization / Revenue 1,10x 1,02x
    EV / Revenue - -
    EV / EBITDA - -
    Yield (DPS / Price) 3,48% 3,86%
    Price to book (Price / BVPS) 1,59x 1,46x
    Profitability 2017e 2018e
    Operating Margin (EBIT / Sales) 13,0% 13,6%
    operating Leverage (Delta EBIT / Delta Sales) 1,34x 1,59x
    Net Margin (Net Profit / Revenue) 7,87% 8,52%
    ROA (Net Profit / Asset) 6,48% 7,25%
    ROE (Net Profit / Equities) 12,1% 12,8%
    Rate of Dividend 47,4% 44,9%
    1. sevilla2014 sevilla2014 está desconectado
  • Interesante análisis

    PGC’s recent acquisitions (predominantly consumables and service businesses) have been performing better than recognised (see page 5), which has significant implications for the growth it is likely to deliver in the future both from its current businesses and the acquisitions that are clearly going to be made. The long term growth we expect sets it apart from comparative companies with similar health related product offerings and makes us think more about the way in which GUD has recently been re-rated in response to its acquisition/divestment program. We believe, based on PGC’s register and limited broker coverage that mainstream investors are yet to consider this and that PGC is essentially undiscovered. Our 12 month TP is $0.95, however with acquisitions we will look to reassess our TP again. BUY.

    1. sevilla2014 sevilla2014 está desconectado
  • Buenísimos resultados

    The Paragon Care Ltd (ASX: PGC) share price rose 8% to $0.88 this morning, after the company released its annual report for 2017. Here’s what you need to know:
    • Revenue rose 25% to $117 million
    • Net profit after tax (NPAT) rose 35% to $10 million
    • Earnings per share rose 11% to 6.2 cents per share
    • Dividends of 3 cents per share
    • Total borrowings of $37 million
    • Cash at bank of $18.5 million
    So What?
    Another strong year for Paragon, with improvements in performance across most important metrics, including net debt, inventory turnover, and margins. Paragon hit its target range of between 5-6 times inventory turnover for the first time this year, reflecting improving sales that is reflected in earnings.
    Likewise, earnings before interest, tax, depreciation and amortisation (EBITDA) margins improved from 13% to 14.6%, just below management’s target of 15%. Revenue of $117 million is well shy of management’s $250 million target. This means that Paragon appears to have plenty of room to grow revenues, although it may not be able to generate much more profit per $1 of sales. As a result, revenue growth could become one of the more important indicators of the company’s growth in the future.

    1. sevilla2014 sevilla2014 está desconectado
  • Nuevo tiróncito y se pone en 93 c.
    1. sevilla2014 sevilla2014 está desconectado
  • Paragon surges, with more upside possible

    Published on: Aug 9, 2017 | by Trevor Hoey
    Shares in healthcare equipment group, Paragon Care (ASX: PGC) spiked from Friday’s close of 81 cents to hit an intraday high of 93 cents on Monday. This occurred under the highest daily volumes recorded in the last five years. The intraday high was repeated again on Tuesday.
    It should be noted share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
    Interestingly, the provider of medical equipment, devices and consumables to the health care industry has traded as high as 94 cents during its circa 10 year history as an ASX listed entity, and it could be technical selling that is currently keeping a lid on the company’s share price.
    Certainly, the result appeared to warrant a rerating as the impressive key financials below indicate.

    While revenues were broadly in line with management’s guidance, there was a slight outperformance at the EBITDA line.
    Brokers see further upside

    As indicated by John Hester from Bell Potter, PGC is best assessed on its earnings per share performance. As a growth by acquisition story, the company has issued new shares over the last two years, effectively diluting earnings per share.
    Consequently, using this measure takes into account the impact of issuing scrip for all or part consideration in relation to acquisitions.
    Bell Potter is forecasting earnings per share to increase to 6.9 cents in fiscal 2018, implying a PE multiple of 13.4 relative to its 12 month high of 93 cents. This represents a 50% discount to the broader sector average PE multiple of 26.8.
    Of course broker projections and price targets are only estimates and may not be met.
    However, some of the larger blue-chip companies tend to push the average multiple higher than what is normally representative of the mid-tier players.
    The broker reactions have been interesting with Bell Potter maintaining its buy recommendation and slightly increasing its price target to $1.02.
    By contrast, Ian Christie from Argonaut views the current price as good value with his valuation of $1.12 implying upside of 20% to the group’s current trading range. He expects PGC to achieve organic growth of 10% per annum over the next two years with EBITDA margins of circa 15%.
    Again, broker projections should only be taken into account with all publically available information.

    PGC’s Managing Director, Mark Simari was relatively upbeat with his outlook statement, saying that the company is well-placed to deliver growth in future years, driven by a combination of organic and acquisitive growth with the e-health sector offering a new revenue stream.
    The addition of services and maintenance contracts will also help, as they provide recurring income to complement revenues generated from the sale of new equipment.
    1. sevilla2014 sevilla2014 está desconectado
  • Video de análisis de la compañía. Yo le veo crecimiento en los próximos años. Mientras la vea con este crecimiento, la mantendré.
    Actualmente tiene un per 15 y ha tenido un crecimiento por acción de más del 30% en el semestre. Le veo bastante recorrido

En Link World Network S.L. utilizamos cookies de Google Analytics para realizar un análisis del tráfico web que recibimos y para analizar el comportamiento de los visitantes de nuestra web. También utilizamos cookies de Google Adsense para la gestión de espacios publicitarios. Si sigues navegando por nuestra web entenderemos que aceptas el uso de estas cookies. Más información sobre las cookies que utilizamos: Política de Cookies.